Xinjiang Baihuacun Co Ltd (600721) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xinjiang Baihuacun Co Ltd (600721) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥17.27 Million ≈ $2.53 Million USD) by net assets (CN¥793.82 Million ≈ $116.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xinjiang Baihuacun Co Ltd (600721) net asset quality to measure how much of total assets are equity-financed.
Xinjiang Baihuacun Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Xinjiang Baihuacun Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xinjiang Baihuacun Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Xinjiang Baihuacun Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xinjiang Baihuacun Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiangyang Automobile Bearing Co Ltd
SHE:000678
|
0.094x |
|
Mystate Ltd
AU:MYS
|
0.140x |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
-0.044x |
|
JinJian Cereals Industry Co Ltd
SHG:600127
|
0.039x |
|
Shanghai Golden Bridge
SHG:603918
|
0.043x |
|
BRASKEM PFD ADR/2 O.N.
F:BRD
|
0.055x |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
0.036x |
|
Shanghai Sinotec Co Ltd
SHG:603121
|
0.048x |
Annual Cash Flow Conversion Efficiency for Xinjiang Baihuacun Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Xinjiang Baihuacun Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Xinjiang Baihuacun Co Ltd (600721) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥803.14 Million ≈ $117.52 Million |
CN¥32.94 Million ≈ $4.82 Million |
0.041x | -61.24% |
| 2024-12-31 | CN¥758.58 Million ≈ $111.00 Million |
CN¥80.29 Million ≈ $11.75 Million |
0.106x | +20.47% |
| 2023-12-31 | CN¥706.62 Million ≈ $103.40 Million |
CN¥62.08 Million ≈ $9.08 Million |
0.088x | +10.20% |
| 2022-12-31 | CN¥667.02 Million ≈ $97.61 Million |
CN¥53.18 Million ≈ $7.78 Million |
0.080x | +57.57% |
| 2021-12-31 | CN¥686.25 Million ≈ $100.42 Million |
CN¥34.72 Million ≈ $5.08 Million |
0.051x | +235.65% |
| 2020-12-31 | CN¥624.16 Million ≈ $91.33 Million |
CN¥-23.28 Million ≈ $-3.41 Million |
-0.037x | -424.03% |
| 2019-12-31 | CN¥954.70 Million ≈ $139.70 Million |
CN¥-6.80 Million ≈ $-994.38K |
-0.007x | -108.13% |
| 2018-12-31 | CN¥919.58 Million ≈ $134.56 Million |
CN¥80.55 Million ≈ $11.79 Million |
0.088x | +402.05% |
| 2017-12-31 | CN¥1.73 Billion ≈ $253.60 Million |
CN¥-50.26 Million ≈ $-7.35 Million |
-0.029x | +38.46% |
| 2016-12-31 | CN¥2.30 Billion ≈ $336.33 Million |
CN¥-108.32 Million ≈ $-15.85 Million |
-0.047x | -105.06% |
| 2015-12-31 | CN¥455.10 Million ≈ $66.60 Million |
CN¥423.58 Million ≈ $61.98 Million |
0.931x | +359.15% |
| 2014-12-31 | CN¥997.28 Million ≈ $145.93 Million |
CN¥202.16 Million ≈ $29.58 Million |
0.203x | +4033.04% |
| 2013-12-31 | CN¥1.35 Billion ≈ $197.86 Million |
CN¥6.63 Million ≈ $970.41K |
0.005x | -98.42% |
| 2012-12-31 | CN¥1.10 Billion ≈ $161.59 Million |
CN¥342.00 Million ≈ $50.05 Million |
0.310x | -39.25% |
| 2011-12-31 | CN¥1.10 Billion ≈ $160.64 Million |
CN¥559.64 Million ≈ $81.89 Million |
0.510x | +57.70% |
| 2010-12-31 | CN¥1.05 Billion ≈ $153.51 Million |
CN¥339.11 Million ≈ $49.62 Million |
0.323x | +3376.14% |
| 2009-12-31 | CN¥361.61 Million ≈ $52.92 Million |
CN¥-3.57 Million ≈ $-522.12K |
-0.010x | -127.73% |
| 2008-12-31 | CN¥344.28 Million ≈ $50.38 Million |
CN¥12.25 Million ≈ $1.79 Million |
0.036x | +8.30% |
| 2007-12-31 | CN¥337.41 Million ≈ $49.37 Million |
CN¥11.09 Million ≈ $1.62 Million |
0.033x | -90.13% |
| 2006-12-31 | CN¥19.48 Million ≈ $2.85 Million |
CN¥6.48 Million ≈ $948.37K |
0.333x | -89.36% |
| 2005-12-31 | CN¥2.59 Million ≈ $378.62K |
CN¥8.10 Million ≈ $1.18 Million |
3.129x | +615.11% |
| 2004-12-31 | CN¥218.65 Million ≈ $32.00 Million |
CN¥95.66 Million ≈ $14.00 Million |
0.438x | +249.96% |
| 2003-12-31 | CN¥229.91 Million ≈ $33.64 Million |
CN¥-67.07 Million ≈ $-9.81 Million |
-0.292x | -55.16% |
| 2002-12-31 | CN¥178.77 Million ≈ $26.16 Million |
CN¥-33.61 Million ≈ $-4.92 Million |
-0.188x | -170.68% |
| 2001-12-31 | CN¥122.68 Million ≈ $17.95 Million |
CN¥32.63 Million ≈ $4.78 Million |
0.266x | +1147.30% |
| 2000-12-31 | CN¥130.41 Million ≈ $19.08 Million |
CN¥-3.31 Million ≈ $-484.70K |
-0.025x | -1168.25% |
| 1999-12-31 | CN¥221.52 Million ≈ $32.41 Million |
CN¥-443.64K ≈ $-64.92K |
-0.002x | +98.47% |
| 1998-12-31 | CN¥273.24 Million ≈ $39.98 Million |
CN¥-35.82 Million ≈ $-5.24 Million |
-0.131x | -- |
About Xinjiang Baihuacun Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical scienc… Read more